AstraZeneca had announced the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of...

Gilead has agreed to acquire CymaBay, a Newark, California-based clinical-stage bio/pharmaceutical company, for $4.3 billion. CymaBay’s lead candidate is seladelpar, an oral drug for treating primary biliary cholangitis (PBC), a rare, chronic, cholestatic liver disease. Under the...

Kyowa Kirin has agreed to acquire gene therapy developer Orchard Therapeutics for up to $477.6 million, to develop several biopharmaceutical candidates in areas including oncology and autoimmune diseases. Under the terms of the agreement, Kyowa will acquire Orchard for $16 per...

    Sanofi has agreed to buy US biotech firm Inhibrx in a deal valued at up to $2.2bn, bolstering its drug development portfolio with an experimental treatment for a rare genetic disease. Under the terms of the agreement, Sanofi will acquire all outstanding shares of...

    Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million. Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a...

    GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range. GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start Phase II trials for the treatment of...

  Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access to Acer’s rare...

    Alkermes plc, had announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the...

  Rain Oncology Inc, had announced that it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain Oncology. Privately held Pathos AI, a company focused on leveraging machine learning and real-world data in drug development, will make a cash...

Bristol Myers Squibb had announced a definitive merger agreement under that it will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both...